The economic implications of noninvasive molecular testing for cardiac allograft rejection

Roger W. Evans, Gavin E. Williams, Helen M. Baron, Mario C. Deng, Howard J. Eisen, Sharon A. Hunt, Mahmud M. Khan, Jon A. Kobashigawa, Eric N. Marton, Mandeep R. Mehra, Seema R. Mital

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Endomyocardial biopsy is the mainstay for monitoring cardiac allograft rejection. A noninvasive strategy-peripheral blood gene expression profiling of circulating leukocytes-is an alternative with proven benefits, but unclear economic implications. Financial data were obtained from five cardiac transplant centers. An economic evaluation was conducted to compare the costs of outpatient biopsy with those of a noninvasive approach to monitoring cardiac allograft rejection. Hospital outpatient biopsy costs averaged $3297, excluding reimbursement for professional fees. Costs to Medicare and private payers averaged $3581 and $4140, respectively. A noninvasive monitoring, test can reduce biopsy utilization. The savings to health care payers in the United States can be conservatively estimated at approximately $12.0 million annually. Molecular testing using gene expression profiling of peripheral circulating leukocytes is a new technology that offers physicians a noninvasive, less expensive alternative to endomyocardial biopsy for monitoring allograft rejection in cardiac transplant patients.

Original languageEnglish (US)
Pages (from-to)1553-1558
Number of pages6
JournalAmerican Journal of Transplantation
Volume5
Issue number6
DOIs
StatePublished - Jun 1 2005

Fingerprint

Allografts
Economics
Biopsy
Gene Expression Profiling
Costs and Cost Analysis
Leukocytes
Outpatients
Transplants
Fees and Charges
Medicare
Cost-Benefit Analysis
Technology
Delivery of Health Care
Physicians

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Evans, Roger W. ; Williams, Gavin E. ; Baron, Helen M. ; Deng, Mario C. ; Eisen, Howard J. ; Hunt, Sharon A. ; Khan, Mahmud M. ; Kobashigawa, Jon A. ; Marton, Eric N. ; Mehra, Mandeep R. ; Mital, Seema R. / The economic implications of noninvasive molecular testing for cardiac allograft rejection. In: American Journal of Transplantation. 2005 ; Vol. 5, No. 6. pp. 1553-1558.
@article{91ca584a37d6456396056298eedf6861,
title = "The economic implications of noninvasive molecular testing for cardiac allograft rejection",
abstract = "Endomyocardial biopsy is the mainstay for monitoring cardiac allograft rejection. A noninvasive strategy-peripheral blood gene expression profiling of circulating leukocytes-is an alternative with proven benefits, but unclear economic implications. Financial data were obtained from five cardiac transplant centers. An economic evaluation was conducted to compare the costs of outpatient biopsy with those of a noninvasive approach to monitoring cardiac allograft rejection. Hospital outpatient biopsy costs averaged $3297, excluding reimbursement for professional fees. Costs to Medicare and private payers averaged $3581 and $4140, respectively. A noninvasive monitoring, test can reduce biopsy utilization. The savings to health care payers in the United States can be conservatively estimated at approximately $12.0 million annually. Molecular testing using gene expression profiling of peripheral circulating leukocytes is a new technology that offers physicians a noninvasive, less expensive alternative to endomyocardial biopsy for monitoring allograft rejection in cardiac transplant patients.",
author = "Evans, {Roger W.} and Williams, {Gavin E.} and Baron, {Helen M.} and Deng, {Mario C.} and Eisen, {Howard J.} and Hunt, {Sharon A.} and Khan, {Mahmud M.} and Kobashigawa, {Jon A.} and Marton, {Eric N.} and Mehra, {Mandeep R.} and Mital, {Seema R.}",
year = "2005",
month = "6",
day = "1",
doi = "10.1111/j.1600-6143.2005.00869.x",
language = "English (US)",
volume = "5",
pages = "1553--1558",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "6",

}

Evans, RW, Williams, GE, Baron, HM, Deng, MC, Eisen, HJ, Hunt, SA, Khan, MM, Kobashigawa, JA, Marton, EN, Mehra, MR & Mital, SR 2005, 'The economic implications of noninvasive molecular testing for cardiac allograft rejection', American Journal of Transplantation, vol. 5, no. 6, pp. 1553-1558. https://doi.org/10.1111/j.1600-6143.2005.00869.x

The economic implications of noninvasive molecular testing for cardiac allograft rejection. / Evans, Roger W.; Williams, Gavin E.; Baron, Helen M.; Deng, Mario C.; Eisen, Howard J.; Hunt, Sharon A.; Khan, Mahmud M.; Kobashigawa, Jon A.; Marton, Eric N.; Mehra, Mandeep R.; Mital, Seema R.

In: American Journal of Transplantation, Vol. 5, No. 6, 01.06.2005, p. 1553-1558.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The economic implications of noninvasive molecular testing for cardiac allograft rejection

AU - Evans, Roger W.

AU - Williams, Gavin E.

AU - Baron, Helen M.

AU - Deng, Mario C.

AU - Eisen, Howard J.

AU - Hunt, Sharon A.

AU - Khan, Mahmud M.

AU - Kobashigawa, Jon A.

AU - Marton, Eric N.

AU - Mehra, Mandeep R.

AU - Mital, Seema R.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Endomyocardial biopsy is the mainstay for monitoring cardiac allograft rejection. A noninvasive strategy-peripheral blood gene expression profiling of circulating leukocytes-is an alternative with proven benefits, but unclear economic implications. Financial data were obtained from five cardiac transplant centers. An economic evaluation was conducted to compare the costs of outpatient biopsy with those of a noninvasive approach to monitoring cardiac allograft rejection. Hospital outpatient biopsy costs averaged $3297, excluding reimbursement for professional fees. Costs to Medicare and private payers averaged $3581 and $4140, respectively. A noninvasive monitoring, test can reduce biopsy utilization. The savings to health care payers in the United States can be conservatively estimated at approximately $12.0 million annually. Molecular testing using gene expression profiling of peripheral circulating leukocytes is a new technology that offers physicians a noninvasive, less expensive alternative to endomyocardial biopsy for monitoring allograft rejection in cardiac transplant patients.

AB - Endomyocardial biopsy is the mainstay for monitoring cardiac allograft rejection. A noninvasive strategy-peripheral blood gene expression profiling of circulating leukocytes-is an alternative with proven benefits, but unclear economic implications. Financial data were obtained from five cardiac transplant centers. An economic evaluation was conducted to compare the costs of outpatient biopsy with those of a noninvasive approach to monitoring cardiac allograft rejection. Hospital outpatient biopsy costs averaged $3297, excluding reimbursement for professional fees. Costs to Medicare and private payers averaged $3581 and $4140, respectively. A noninvasive monitoring, test can reduce biopsy utilization. The savings to health care payers in the United States can be conservatively estimated at approximately $12.0 million annually. Molecular testing using gene expression profiling of peripheral circulating leukocytes is a new technology that offers physicians a noninvasive, less expensive alternative to endomyocardial biopsy for monitoring allograft rejection in cardiac transplant patients.

UR - http://www.scopus.com/inward/record.url?scp=20544443149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20544443149&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2005.00869.x

DO - 10.1111/j.1600-6143.2005.00869.x

M3 - Article

C2 - 15888068

AN - SCOPUS:20544443149

VL - 5

SP - 1553

EP - 1558

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 6

ER -